Big pharma spent billions this week buying biotechs it could have built

Biotech & Longevity 3 min 80 sources

A run of deals — Vertex's $10bn Crinetics buyout, Novartis, Ipsen, United Therapeutics — shows the giants outsourcing early science to small firms and paying only for winners.

Key takeaways

Big drugmakers spent over $12 billion this week buying small biotechs — led by Vertex's $10bn deal for Crinetics — rather than inventing the drugs themselves.
The giants face a patent cliff as top sellers lose protection, so they let small firms run the risky early science and pay to acquire the winners.
The upfront fees and milestone payments for those buyouts eventually land in the price of the finished drug, paid by patients and health systems.

The biggest drug companies did very little inventing this week. They went shopping instead. In the space of a few days, a run of acquisitions worth well over $12 billion moved late-stage drugs and platforms from small biotechs into the pipelines of the giants [1][13][29][8][35]. This is how a large slice of modern medicine now gets made: the small firms run the risky early science, and the big ones buy the survivors.

The deals

The headline number was Vertex’s. On Monday the company, best known for its cystic fibrosis drugs, agreed to buy Crinetics Pharmaceuticals for about $10 billion — its push to grow beyond the one disease that built it [13][52]. Crinetics makes hormone drugs, including one recently approved for a rare pituitary tumour condition [52].

Around it, a cluster of smaller deals landed the same week. Novartis paid $1.1 billion upfront for the UK biotech Myricx Bio, buying its way into antibody-drug conjugates — cancer drugs that use an antibody to carry a toxic payload straight to a tumour cell, sparing healthy tissue [29]. Novartis had stayed out of that field for years; it decided a buyout was faster than building [29].

The French firm Ipsen bought two companies in three days, including Switzerland’s Memo Therapeutics for €700 million (about $770 million) for an antibody aimed at a virus that can wreck kidney transplants — a problem with no approved treatment today [8]. United Therapeutics paid $140 million for Thymmune, a preclinical startup working on the thymus, the chest organ that trains the body’s T cells and shrinks as we age [35]. And MeiraGTx pulled in up to $400 million from an investor to push two gene therapies toward market [36].

Why it happens now

The pattern isn’t random. Big drugmakers face what the industry calls a patent cliff: over the next few years, several of their best-selling drugs lose patent protection and cheap copies flood in, taking the revenue with them. To fill the gap, they need new drugs — and the cheapest way to get one that already works is to buy it.

Meanwhile the small biotechs have spent lean years. Many burned through cash during a long funding drought and are happy, or forced, to sell. When the buyers have full wallets and the sellers are running low, deals happen. STAT called it a biotech M&A boom [13].

The bill, and who reads it

A buyout isn’t free science. Novartis paid $1.1 billion upfront for a drug still in development [29]; the AlzeCure Alzheimer’s asset licensed this week could trigger over $2.2 billion in later payments if it works [6]. Those numbers eventually sit inside the price of the finished drug. The small firm took the early risk; the big firm took the winner; and the cost of both the failures and the finder’s fee lands, in the end, in what a patient or a health system pays.

That’s the tension running under a good week for dealmakers. It moves promising drugs closer to patients faster than any one company could manage alone. It also concentrates the finished medicines — and the pricing power over them — in a handful of very large hands.

Elsewhere in the labs

Not everything was a cheque. Roche reported that its experimental lung-cancer drug divarasib beat two approved rivals, Amgen’s and Bristol Myers Squibb’s, in a head-to-head phase 3 trial of 338 patients — the large, final-stage test before approval [10][48]. It’s an unusual, direct win over the incumbents, though Roche has not yet released the survival numbers, so the size of the benefit is still unknown [10].

The US regulator, the FDA, approved a new drug from Vera Therapeutics for IgA nephropathy, a chronic kidney disease driven by the immune system [67]. And two aging studies added mechanism, not cures: one team found a molecular “switch” (a gene called DEAF1) that helps explain why exercise keeps old muscle healthy — shown in cells and tissue, not yet a pill [49]; another identified a possible new way brain cells die in Alzheimer’s, a finding that points at a target rather than a treatment [51].

02 · Lesson · why it matters

Why the biggest players would rather buy the winner than run the race

When you can't tell which bet will pay off, the smart move isn't to bet harder — it's to let a hundred others bet, and buy whoever wins.

A strange thing for a giant to do

Vertex has more scientists, more money, and more history than the small firm it just agreed to buy for $10 billion. On paper it could have tried to invent the same drugs itself. It didn’t. Nor did Novartis, or Ipsen, or United Therapeutics. In a single week the biggest names in medicine spent billions buying drugs that other, smaller companies had already discovered.

That looks backwards. Shouldn’t the company with the most resources be the one doing the inventing?

It isn’t backwards. It’s a rational response to one hard fact: nobody knows in advance which drug will work.

The problem is that most attempts fail

A new drug is a long, expensive coin-flip. Most candidates that look promising in a dish, or in a mouse, never help a single human. The failures aren’t rare exceptions — they’re the normal outcome. For every drug that reaches a patient, a great many died quietly in a lab.

If you’re a giant, that’s a miserable way to spend money. Pour a billion dollars into one internal program and the most likely result is a billion-dollar hole. You can’t tell ahead of time which idea is the good one — if you could, everyone would only chase good ones.

So the giant makes a different move. It doesn’t try to guess the winner. It lets the whole field guess for it.

Let a hundred small firms run the experiments

Small biotechs are built for exactly this. Each one is a concentrated bet on a single idea — a new payload, a new target, a virus nobody else is treating. Most will fail and quietly fold. A few will produce a drug that actually works.

The giant sits back and watches the field sort itself out. It doesn’t pay for the failures — those are somebody else’s sunk cost. It waits until an idea has proven itself in a real trial, then it buys that one company. It’s paying a premium to skip the guessing. The price of the winner already has the failures baked in, but it’s still cheaper than having run all the losing bets yourself.

This is a division of labour, drawn along a line most of us never see: the small firms specialise in trying, and the giant specialises in choosing and scaling. The riskiest part of the work — the early, most-likely-to-fail part — has been quietly pushed to the edges, onto people with the least money to absorb it.

The same shape, far from a lab

You already know this pattern; you’ve just seen it wear other clothes.

A big record label doesn’t find new sounds in a boardroom. Thousands of unsigned musicians play empty rooms for years; the label signs the handful who’ve already drawn a crowd. A studio watches independent films win at festivals, then buys the hit. A supermarket lets small brands prove there’s demand, then launches its own copy or buys the brand outright. In each case the powerful player lets a crowd of smaller ones absorb the risk of failing, and pays only for the proof.

It’s efficient. It also quietly arranges the world so that the people who take the early, unpaid risk are rarely the people who end up holding the finished thing — or setting its price.

Where you’re standing in this

None of this stays inside the industry. The premium the giant pays for the winner, and the cost of all the failures folded into that premium, doesn’t vanish. It travels forward into the price of the finished drug — into what a health system spends, what an insurer charges, what shows up when you or someone you love needs the medicine.

You are not outside this arrangement, watching dealmakers trade. You’re at the far end of it, holding the receipt for a system that works this way on purpose — one that genuinely does move real drugs to real patients faster than any single company could, and, at the same time, concentrates those drugs and their prices into very few hands. Both of those are true at once. Seeing that the same clever structure delivers the medicine and sets what it costs is not a reason to cheer or to sneer. It’s a reason to hold your certainty about who the heroes and villains are a little more loosely — and to notice how much of the machine any one seat, including yours, can actually see.

03 · Lab · your turn

Build or Buy the Winner

Rehearse the drug giant's bet — invent in-house and eat every failure, or pay a premium to buy only proven drugs, and feel who carries the risk.

04 · Hope · carry this

A drug that saves a life rarely comes from one lab or one giant — it comes from a hundred small firms trying things that mostly fail, and a system that still finds the one that works and carries it the last mile to a patient.